Glenmark Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Glenmark Pharmaceuticals hat ein Gesamteigenkapital von ₹78.5B und eine Gesamtverschuldung von ₹9.9B, wodurch sich der Verschuldungsgrad auf 12.6% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen ₹143.6B bzw. ₹65.1B. Glenmark Pharmaceuticals Das EBIT des Unternehmens beträgt ₹14.5B, so dass der Zinsdeckungsgrad 2.8 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von ₹16.6B.

Wichtige Informationen

12.6%

Verhältnis von Schulden zu Eigenkapital

₹9.91b

Verschuldung

Zinsdeckungsgrad	1.2x
Bargeld	₹16.59b
Eigenkapital	₹78.48b
Gesamtverbindlichkeiten	₹65.11b
Gesamtvermögen	₹143.59b

Jüngste Berichte zur Finanzlage

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Jul 03

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Mar 22

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Jun 20

Recent updates

Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 06

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Jun 16

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

May 08

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Mar 09

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Dec 07

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 23

Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Sep 17

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 30

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 28

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Jul 03

A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

May 28

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Mar 22

Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Feb 14

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Oct 12

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 21

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 29

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Jun 20

There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings

Jun 04

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued

May 05

If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late

Mar 25

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Jan 18

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Dec 13

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: GLENMARKDie kurzfristigen Aktiva des Unternehmens (₹74.3B) übersteigen seine kurzfristigen Passiva (₹58.2B).

Langfristige Verbindlichkeiten: GLENMARKDie kurzfristigen Vermögenswerte des Unternehmens (₹74.3B) übersteigen seine langfristigen Verbindlichkeiten (₹6.9B).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: GLENMARK über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: GLENMARK Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 79.4% auf 12.6% zurückgegangen.

Schuldendeckung: GLENMARKDer operative Cashflow des Unternehmens ist negativ, so dass die Schulden nicht ausreichend gedeckt sind.

Zinsdeckung: GLENMARKDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (2.8x Deckung) nicht gut gedeckt.

Glenmark Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Recent updates

Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 14, 2024

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Price target increased by 9.7% to ₹1,056

Full year 2024 earnings: EPS and revenues miss analyst expectations

Glenmark Pharmaceuticals Limited Recommends Dividend for the Financial Year 2023-24

Glenmark Pharmaceuticals Receives ANDA Approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%

Glenmark Pharmaceuticals Limited to Report Q4, 2024 Results on May 24, 2024

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

Now 24% overvalued after recent price rise

Nirma Limited completed the acquisition of 75% stake in Glenmark Life Sciences Limited (NSEI:GLS) from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) (GPL).

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Price target increased by 11% to ₹907

Now 20% overvalued after recent price rise

Now 21% overvalued after recent price rise

Third quarter 2024 earnings released: ₹16.66 loss per share (vs ₹9.66 profit in 3Q 2023)

Glenmark Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Glenmark Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 10, 2023

Glenmark Pharma Launches Triple-Drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-Morbidities

Glenmark Pharmaceuticals Receives ANDA Approval for Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg

Nirma Limited entered into a definitive agreement to acquire 75% stake in Glenmark Life Sciences Limited (NSEI:GLS) from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) for INR 56.5 billion.

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Glenmark Pharmaceuticals Divests 75% in GLS to Nirma

Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Glenmark Pharmaceuticals Limited Announces Management Promotions

Upcoming dividend of ₹2.50 per share at 0.3% yield

Insufficient new directors

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2023

ChrysCapital Still in Race to Buy Controlling Stake in Glenmark Life Sciences

Price target increased by 12% to ₹689

First quarter 2024 earnings released: EPS: ₹5.31 (vs ₹6.82 in 1Q 2023)

Glenmark Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 11, 2023

Nirma, Sekhmet Pharmaventures Reportedly Vie for $731 Million Glenmark Life Stake

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Miller Law LLC and Motley Rice LLC Announce a Proposed Settlement in re Zetia (Ezetimibe) Antitrust Litigation

A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Full year 2023 earnings released: EPS: ₹10.53 (vs ₹33.37 in FY 2022)

Glenmark Pharmaceuticals Limited Recommends Dividend for the Financial Year 2022-23

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Third quarter 2023 earnings released: EPS: ₹9.66 (vs ₹7.86 in 3Q 2022)

Glenmark Pharmaceuticals Limited Launches in India Unique I.V. Injection Formulation

Glenmark Pharmaceuticals Launches the Sacubitril + Valsartan Tablets in India for the Treatment of Heart Failure

Glenmark Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 10, 2023

Glenmark Pharmaceuticals Limited Receives Final Approval by United States Food & Drug Administration for Nicardipine Hydrochloride Capsules, 20 Mg and 30 Mg

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Razel Franchise For India And Nepal Region from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) for INR3.1 billion.

Second quarter 2023 earnings released: EPS: ₹9.23 (vs ₹9.13 in 2Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹9.23 (vs ₹9.13 in 2Q 2022)

Glenmark Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 11, 2022

Glenmark Pharmaceuticals Limited to Launch Teneligliptin + Dapagliflozin Fixed Dose Combination, for Adults with Type 2 Diabetes, Having Comorbidities

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Glenmark Launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in Adults

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Upcoming dividend of ₹2.50 per share

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Glenmark Pharmaceuticals Limited, Annual General Meeting, Sep 27, 2022

Glenmark Pharmaceuticals Limited, Annual General Meeting, Sep 27, 2022

First quarter 2023 earnings released: EPS: ₹6.82 (vs ₹10.86 in 1Q 2022)

Glenmark Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 10, 2022

Glenmark Pharmaceuticals Limited and SaNOtize Research and Development Corp. Announces Peer Reviewed Publication of Its Phase 3 Clinical Trials on Sanotize's Novel Nitric Oxide Nasal Spray for Covid-19 in Lancet Journal

Glenmark Pharmaceuticals Ltd. Launch's India's First Topical Minocycline 4% Gel for the Treatment of Moderate to Severe Acne

Glenmark Pharmaceuticals Limited Launches Sitagliptin and its Fixed Dose Combinations for Adults with Type 2 Diabetes in India

Upcoming dividend of ₹2.50 per share

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Glenmark Pharmaceuticals Limited Launches Novel Fixed-Dose Combination Drug - Indacaterol + Mometasone for Patients Suffering from Uncontrolled Asthma, in India